Editorial: Psoriatic disease: Concepts and implications

Journal of the European Academy of Dermatology and Venereology

Volumn 24, Issue 6, 2010, Pages 627-630

  Scarpa, R ^a   Altomare, G ^b   Marchesoni, A ^c   Balato, N ^a   Matucci Cerinic, M ^d   Lotti, T ^d   Olivieri, I ^e   Vena, G A ^f   Salvarani, C ^g   Valesini, G ^h,i   Giannetti, A ^b,e  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b IRCCS   (Italy)

^c UOC DH of Rheumatology   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

^e SAN CARLO HOSPITAL   (Italy)

^f UNIVERSITY OF BARI   (Italy)

^g University of Bari ^*  (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ALEFACEPT; CORTICOSTEROID; CYCLOSPORIN A; LEFLUNOMIDE; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB;

ANGIOGENESIS; CLINICAL FEATURE; DISEASE COURSE; DISEASE MODEL; DISEASE SEVERITY; EDITORIAL; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOLOGY; NONHUMAN; PATHOGENESIS; PHOTOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; PSORIASIS; PSORIATIC ARTHRITIS; SKIN MANIFESTATION; HISTORY; PATHOLOGY; PATHOPHYSIOLOGY; SKIN;

ARTHRITIS, PSORIATIC; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; PSORIASIS; SKIN;

EID: 77952222383     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03574.x     Document Type: Editorial

References (37)

1. Scarpa R, Ayala F, Caporaso N, Olivieri I. Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol 2006 33 : 210 212.
2. Alibert JL. Précis théorique sur les maladies de la peau. Caille et Ravier
3. Bazin P. Leçons théoretiques et cliniques sur les affections cutanées de nature arthritique et arthreux. Delahaye
4. Bourdillon C. Psoriasis et arthropathies. MD Thesis, University of Paris
5. Wright V. Rheumatism and psoriasis: a re-evaluation. Am J Med 1959 27 : 454 462.
6. Blumberg BS, Bunim J, Calkius E et al. Nomenclature and classification of arthritis and rheumatism (tentative) accepted by the American Rheumatism Association. Bull Rheum Dis 1964 14 : 3391 3396.
7. Moll JMH. Family study of psoriatic arthritis. MD Thesis, Univerity of Oxford
8. Moll JM, Wright V. Familial occurrence of psoriatic arthritis. Ann Rheum Dis 1973 32 : 181 201.
9. Wright V, Moll JMH. Seronegative Polyarthritis. Elsevier North Holland
10. Scarpa R, Oriente P, Pucino A et al. Psoriatic arthritis in psoriatic patients. Br J Rheumatol 1984 23 : 246 250.
11. Salvarani C, Lo Scocco G, Macchioni PL et al. Presence of psoriatic arthritis in Italian psoriatic patients. J Rheumatol 1995 22 : 1499 1503.
12. Scarpa R, Cosentini E, Manguso F et al. Clinical and genetic aspects of psoriatic arthritis "sine psoriasis". J Rheumatol 2003 30 : 2638 2640.
13. Ritchlin C. Psoriatic arthritis, B. Pathology and pathogenesis. In Klippel JH, eds. Primer on the Rheumatic Diseases. Springer Ed.
14. Zaba LC, Cardinale I, Gilleaudeau P et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007 13 : 3183 3194.
15. Guttman-Yassky E, Lowes MA, Fuentes-Duculan J et al. Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J Immunol 2008 10 : 7420 7427.
16. Johnson-Huang LM, McNutt NS, Krueger JG, Lowes MA. Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases. J Clin Immunol 2009 29 : 247 256.
17. Monteleone G, Pallone F, MacDonald TT. Interleukin-21:a critical regulator of the balance between effector and regulatory T-cell responses. Trends Immunol 2008 29 : 290 294.
18. Caruso R, Botti E, Sarra M et al. Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med 2009 15 : 1013 1015.
19. Fearon U, Veale DJ. Angiogenesis in arthritis: methodological and analytical details. Methods Mol Med 2007 135 : 343 357.
20. Lories RJ, Luyten FP. Bone morphogenetic proteins in destructive and remodeling arthritis. Arthritis Res Ther 2007 9 : 207.
21. Diarra D, Stolina M, Polzer K et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007 13 : 156 163.
22. Schett G, Zwerina J, David JP. The role of Wnt proteins in arthritis. Nat Clin Pract Rheumatol 2008 4 : 473 480.
23. Scarpa R, Manguso F, D'Arienzo A et al. Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. J Rheumatol 2000 27 : 1241 1246.
24. Jenkins D, Balsitis M, Gallivan S et al. Guidelines for the initial biopsy diagnosis of suspected chronic idiopathic inflammatory bowel disease. The British Society of Gastroenterology Initiative. J Clin Pathol 1997 50 : 93 105.
25. Demetter P, De Vos M, Van Huysse JA et al. Colon mucosa of patients both with spondyloarthritis and Crohn's disease is enriched with macrophages expressing the scavenger receptor CD163. Ann Rheum Dis 2005 64 : 321 324.
26. Mallbris L, Shin DB, Stahle M. Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr Rheumatol Rep 2006 8 : 355 363.
27. Neimann AL, Shin DB, Wong X, Mangolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006 55 : 829 835.
28. Mallbris L, Granat F, Hamsten A, Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006 54 : 614 621.
29. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 2006 32 : 982 986.
30. Gelfand JM, Neimann AL, Shin DB, Wong X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006 296 : 1735 1741.
31. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women - Nurses' Health Study II. Arch Intern Med 2007 167 : 1670 1675.
32. Taylor W, Helliwell P, Mielants H, Marchesoni A, Gladman D, Mease P. ClASsification criteria for Psoriatic ARthritis: results from the CASPAR study. Arthritis Rheum 2006 54 : 2665 2673.
33. Antoni CE, Kavanaugh A, Kirkham B et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005 52 : 1227 1236.
34. Antoni C, Krueger GG, de Vlam K et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005 64 : 1150 1157.
35. Mease PJ, Gladman DD, Ritchlin CT et al. Adalimumab in the treatment of patients with moderately to severely active psoriatic arthritis: results of the ADEPT Trial. Arthritis Rheum 2005 52 : 3279 3289.
36. Mease PJ, Gladman DD, Keystone EC. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2006 54 : 1638 1645.
37. Olivieri I, de Portu S, Salvarani C et al. The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. Rheumatology (Oxford) 2008 47 : 1664 1670.